QDOT MICRO System
Biosense Webster, Inc. · Decision date Nov 23, 2022
What did the FDA approve?
FDA approved the Biosense Webster QDOT MICRO Catheter and related accessory devices on November 23, 2022, under PMA number P210027. The approval covers catheter-based cardiac electrophysiological mapping, including stimulating and recording, and treatment of Type I atrial flutter in patients age 18 or older when used with a compatible RF generator.
The approval also covers drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with compatible three-dimensional electroanatomic mapping systems. The catheter provides real-time contact force measurement between the tip and heart wall, plus location information when used with the CARTO 3 Navigation System. The statement does not include independent proof of safety or clinical effectiveness beyond the approval decision.
FDA approval order statement
Approval for the Biosense Webster QDOT MICRO Catheter and related accessory devices. The device is indicated for catheter-based cardiac electrophysiological mapping (stimulating and recording) and, when used with a compatible RF generator, for the treatment of:1) Type I atrial flutter in patients age 18 or older; and2) Drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with compatible three-dimensional electroanatomic mapping systems. The QDOT MICRO Catheter provides a real-time measurement of contact force between the catheter tip and heart wall, as well as location information when used with CARTO 3 Navigation System.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Nov 23, 2022
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210027
- Regulatory pathway
- Premarket approval application
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- Decision code
- APPR
- Decision date
- Nov 23, 2022
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Catheter, percutaneous, cardiac ablation, for treatment of atrial fibrillation.
- Applicant
- Biosense Webster, Inc.
- Product code
- OAE
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P210027 received
Application receipt date recorded by FDA.
P210027 · FDA decision
APPR
P210027/S018 · Related supplement
QDOT MICRO System
P210027/S019 · Related supplement
QDOT MICRO BI-DIRECTIONAL NAVIGATION CATHETER; QDOT MICRO UNI-DIRECTIONAL NAVIGATION CATHETER
Timeline entries are records held by MedtechLedger for P210027. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210027
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
QDOT MICRO SystemP210027/S018 | Biosense Webster, Inc. | PMA supplement | Sep 10, 2026 | FDA |
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA |
Explore the linked device profile
Other records with product code OAE
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
STOP Persistent AFP100010/S154 | Medtronic Cryocath, LP | PMA supplement | Sep 25, 2026 | FDA |
TactiFlex Ablation Catheter, Sensor EnabledP220013/S034 | ABBOTT MEDICAL | PMA supplement | Sep 22, 2026 | FDA |
| ABBOTT MEDICAL | PMA supplement | Sep 4, 2026 | FDA | |
| ABBOTT MEDICAL | PMA approval | May 18, 2023 | FDA | |
| Medtronic Cryocath, LP | PMA approval | Dec 17, 2010 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biosense Webster, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P210027
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

